Issued Patents All Time
Showing 1–25 of 56 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12428404 | Inhibitors of LRRK2 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2025-09-30 |
| 12338261 | Alvocidib prodrugs having increased bioavailability | Adam Siddiqui-Jain | 2025-06-24 |
| 12275738 | CDK9 inhibitors | Hariprasad Vankayalapati, Zhaoliang Li, Kyle Medley, Dongqing Yan | 2025-04-15 |
| 12091413 | Inhibitors of NEK7 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2024-09-17 |
| 11866423 | Inhibitors of LRRK2 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2024-01-09 |
| 11793802 | Treatment of acute myeloid leukemia (AML) with venetoclax failure | Stephen Patrick Anthony, Michael Vincent McCullar, Susan Carol Smith | 2023-10-24 |
| 11713321 | Inhibitors of NEK7 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2023-08-01 |
| 11712433 | Compositions comprising PKM2 modulators and methods of treatment using the same | Steven L. Warner, Jason Marc Foulks | 2023-08-01 |
| 11578061 | Inhibitors of LRRK2 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2023-02-14 |
| 11529350 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott | 2022-12-20 |
| 11497756 | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib | Adam Siddiqui-Jain, Clifford J. Whatcott, Steven L. Warner | 2022-11-15 |
| 11400091 | AXL kinase inhibitors and use of the same | Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, Jason Marc Foulks, Nozomi Tomimatsu +4 more | 2022-08-02 |
| 11161852 | Inhibitors of NEK7 kinase | John Sai Keong Kauwe, III, Alexis Henri Abel Mollard | 2021-11-02 |
| 11040038 | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same | Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony +3 more | 2021-06-22 |
| 10835537 | Combination therapies for treatment of cancer | Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim | 2020-11-17 |
| 10752594 | JAK1 and ALK2 inhibitors and methods for their use | Alexis Henri Abel Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati | 2020-08-25 |
| 10682356 | Combination therapies for treatment of cancer | Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim | 2020-06-16 |
| 10624880 | Predicting response to alvocidib by mitochondrial profiling | Steven L. Warner | 2020-04-21 |
| 10568887 | Combination therapies for treatment of cancer | Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim | 2020-02-25 |
| 10562925 | Alvocidib prodrugs having increased bioavailability | Adam Siddiqui-Jain | 2020-02-18 |
| 10422788 | Profiling peptides and methods for sensitivity profiling | Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen | 2019-09-24 |
| 10357488 | Predicting response to alvocidib by mitochondrial profiling | Steven L. Warner | 2019-07-23 |
| 10267787 | Profiling peptides and methods for sensitivity profiling | Adam Siddiqui-Jain, Clifford J. Whatcott, Peter W. Peterson, Steven L. Warner, Lars Mouritsen | 2019-04-23 |
| 10259835 | Alvocidib prodrugs having increased bioavailability | Adam Siddiqui-Jain | 2019-04-16 |
| 10202356 | JAK2 and ALK2 inhibitors and methods for their use | Alexis Henri Abel Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati | 2019-02-12 |